Flanagan N G, Ridway J C, Platt C C, Rowlands A J, Whitson A
Department of Haematology, Victoria Hospital, Blackpool, UK.
Clin Lab Haematol. 1989;11(1):17-26. doi: 10.1111/j.1365-2257.1989.tb00170.x.
Earlier studies have indicated a role for serum lactic dehydrogenase (LDH) in haematological and other malignancies. As this is still not a routine test in many units, its value has been re-examined in a retrospective analysis of serum LDH levels in 278 patients with haematological malignancies managed in a single unit. Abnormal levels at diagnosis were found in 42% of these disorders; yet analysis of over 23,000 routine requests for a biochemical screen showed only 4% with an abnormal LDH level. The estimation was also valuable in follow-up of those haematological patients, with rising levels often indicating progressive or relapsing disease even in cases which had shown a normal LDH at diagnosis.
早期研究表明血清乳酸脱氢酶（LDH）在血液系统及其他恶性肿瘤中发挥一定作用。由于在许多科室这仍不是一项常规检查，因此通过对某一科室收治的278例血液系统恶性肿瘤患者的血清LDH水平进行回顾性分析，重新审视了其价值。这些疾病中42%在诊断时LDH水平异常；然而，对超过23000例生化筛查的常规申请分析显示，只有4%的患者LDH水平异常。该检测对于那些血液系统疾病患者的随访也很有价值，即使在诊断时LDH水平正常的病例中，其水平升高通常也表明疾病进展或复发。
